AI Science Tracker

A six-metabolite machine-learning panel and isovalerylcarnitine findings for gastric cancer

Zhejiang Cancer Hospital; and six collaborating clinical centers; Shanghai Jiao Tong University; Zhejiang Chinese Medical University; Wenzhou Medical University; National Cancer Center/National Clinical Research Center for Cancer, China · 27 Oct 2025 · medicine

Discovery

A six-metabolite machine-learning panel and isovalerylcarnitine findings for gastric cancer

In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation. The panel included isovalerylcarnitine (C5), which was lower in cancer plasma and paired tumor tissue; the paper further reported a Mendelian-randomization association and cell-assay evidence linking C5 treatment to reduced gastric-cancer cell migration and invasion through calpain-associated changes in VE-cadherin and MMP2.

Technology: LASSO regression score feature selection with neural-network, support-vector-machine, ridge-regression, logistic-regression and naive-Bayes classifiers

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation.
  • Still unknown: The cohorts were case-control clinical samples and do not establish population-screening performance or improved patient outcomes. The validation cohort contained 453 participants from seven centers; no prospective care-impact trial was reported. Mendelian-randomization evidence is observational genetic-instrument analysis, and cell migration/invasion experiments do not establish a treatment effect in animals or people. The 2024 IDDF abstract (DOI 10.1136/gutjnl-2024-IDDF.267) is an earlier disclosure of this same project, not a separate discovery. Source checked; independent replication not assessed.
  • AI role: Machine-learning feature selection narrowed replicated plasma metabolite signals to a six-feature diagnostic panel, and the specified classifiers constructed/evaluated diagnostic models. The C5 mechanistic work was follow-up metabolomics, Mendelian-randomization, proteomic-correlation and in-vitro experimentation; the record does not imply that machine learning alone established the mechanism.

Evidence sources: https://link.springer.com/article/10.1038/s44321-025-00325-0

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.